Suppr超能文献

国家肌萎缩侧索硬化症登记处:一种研究招募工具。

The National ALS Registry: a recruitment tool for research.

作者信息

Malek Angela M, Stickler David E, Antao Vinicius C, Horton D Kevin

机构信息

Department of Neurosciences, Medical University of South Carolina, 135 Cannon Street, Room 305L, Charleston, South Carolina, 29425, USA.

出版信息

Muscle Nerve. 2014 Nov;50(5):830-4. doi: 10.1002/mus.24421. Epub 2014 Sep 24.

Abstract

INTRODUCTION

Subject recruitment is critical for understanding fatal diseases like ALS, however linking patients with researchers can be challenging. The U.S. population-based National ALS Registry allows recruitment of persons with ALS (PALS) for research opportunities.

METHODS

The Registry's Research Notification Mechanism was used to recruit PALS aged ≥21 years; participants completed a Web-based epidemiologic survey. PALS (n = 2,232) were sent an email describing the study, and 268 surveys were completed.

RESULTS

The mean age (± SD) of eligible participants was 57.7 ± 9.3 years for men and 61.5 ± 8.9 for women. Most were men (63%) and Caucasian (92%). Of 256 potentially eligible participants, 37.5% (n = 96) returned an authorization to disclose protected health information. ALS was confirmed for 94% (83/88) from physician responses.

CONCLUSIONS

This analysis demonstrates the National ALS Registry's usefulness in recruiting PALS for research. This recruitment source can potentially foster the discovery of better treatment options and therapies, and of prevention strategies.

摘要

引言

招募受试者对于了解像肌萎缩侧索硬化症(ALS)这样的致命疾病至关重要,然而将患者与研究人员联系起来可能具有挑战性。美国基于人群的国家ALS登记处允许招募ALS患者(PALS)以获得研究机会。

方法

登记处的研究通知机制用于招募年龄≥21岁的PALS;参与者完成了一项基于网络的流行病学调查。向2232名PALS发送了一封描述该研究的电子邮件,共完成了268份调查问卷。

结果

符合条件的参与者的平均年龄(±标准差),男性为57.7±9.3岁,女性为61.5±8.9岁。大多数是男性(63%)和白种人(92%)。在256名潜在符合条件的参与者中,37.5%(n = 96)返回了披露受保护健康信息的授权。根据医生的回复,94%(83/88)的患者被确诊为ALS。

结论

该分析证明了国家ALS登记处在招募PALS进行研究方面的有用性。这种招募来源有可能促进发现更好的治疗选择和疗法以及预防策略。

相似文献

1
The National ALS Registry: a recruitment tool for research.
Muscle Nerve. 2014 Nov;50(5):830-4. doi: 10.1002/mus.24421. Epub 2014 Sep 24.
3
Prevalence of Amyotrophic Lateral Sclerosis - United States, 2012-2013.
MMWR Surveill Summ. 2016 Aug 5;65(8):1-12. doi: 10.15585/mmwr.ss6508a1.
5
Preliminary Results of National Amyotrophic Lateral Sclerosis (ALS) Registry Risk Factor Survey Data.
PLoS One. 2016 Apr 28;11(4):e0153683. doi: 10.1371/journal.pone.0153683. eCollection 2016.
6
A revision to the United States national ALS registry's algorithm to improve Case-Ascertainment.
Amyotroph Lateral Scler Frontotemporal Degener. 2023 May;24(3-4):230-236. doi: 10.1080/21678421.2022.2121168. Epub 2022 Oct 4.
7
Clinical characteristics of a large cohort of US participants enrolled in the National Amyotrophic Lateral Sclerosis (ALS) Registry, 2010-2015.
Amyotroph Lateral Scler Frontotemporal Degener. 2019 Aug;20(5-6):413-420. doi: 10.1080/21678421.2019.1612435. Epub 2019 May 26.
8
Recruitment of population-based controls for ALS cases from the National ALS Registry.
Amyotroph Lateral Scler Frontotemporal Degener. 2021 Aug;22(5-6):395-400. doi: 10.1080/21678421.2021.1887262. Epub 2021 Apr 16.
9
A brief report on juvenile amyotrophic lateral sclerosis cases in the United States National ALS Registry: 2010-2018.
Amyotroph Lateral Scler Frontotemporal Degener. 2024 Feb;25(1-2):211-213. doi: 10.1080/21678421.2023.2264922. Epub 2024 Jan 23.
10
Amyotrophic lateral sclerosis estimated prevalence cases from 2022 to 2030, data from the national ALS Registry.
Amyotroph Lateral Scler Frontotemporal Degener. 2025 May;26(3-4):290-295. doi: 10.1080/21678421.2024.2447919. Epub 2025 Jan 3.

引用本文的文献

1
Early life events may be the first steps on the multistep path to amyotrophic lateral sclerosis.
Sci Rep. 2024 Nov 18;14(1):28497. doi: 10.1038/s41598-024-78240-6.
2
Comparison of Demographics: National Amyotrophic Lateral Sclerosis Registry and Clinical Trials Data.
J Racial Ethn Health Disparities. 2024 Jul 8. doi: 10.1007/s40615-024-02047-4.
3
Effects of Aided Communication on Communicative Participation for People With Amyotrophic Lateral Sclerosis.
Am J Speech Lang Pathol. 2023 Jul 10;32(4):1450-1465. doi: 10.1044/2023_AJSLP-22-00346. Epub 2023 Jun 19.
6
Are There Modifiable Environmental Factors Related to Amyotrophic Lateral Sclerosis?
Front Neurol. 2018 Apr 6;9:220. doi: 10.3389/fneur.2018.00220. eCollection 2018.
7
Patients with sporadic and familial amyotrophic lateral sclerosis found value in genetic testing.
Mol Genet Genomic Med. 2018 Mar;6(2):224-229. doi: 10.1002/mgg3.360. Epub 2017 Dec 20.
9
Research Registries: A Tool to Advance Understanding of Rare Neuro-Ophthalmic Diseases.
J Neuroophthalmol. 2016 Sep;36(3):317-23. doi: 10.1097/WNO.0000000000000391.

本文引用的文献

2
Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial.
Lancet. 2014 Jun 14;383(9934):2065-2072. doi: 10.1016/S0140-6736(14)60222-1. Epub 2014 Feb 28.
3
Environmental and occupational risk factors for amyotrophic lateral sclerosis: a case-control study.
Neurodegener Dis. 2014;14(1):31-8. doi: 10.1159/000355344. Epub 2013 Nov 12.
4
Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial.
Lancet Neurol. 2013 Nov;12(11):1059-67. doi: 10.1016/S1474-4422(13)70221-7. Epub 2013 Sep 23.
5
The National Amyotrophic Lateral Sclerosis (ALS) Registry.
J Environ Health. 2012 Jul-Aug;75(1):28-30.
6
New considerations in the design of clinical trials for amyotrophic lateral sclerosis.
Clin Investig (Lond). 2011 Oct;1(10):1375-1389. doi: 10.4155/cli.11.127.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验